PP2A inactivation is a crucial step in triggering apoptin-induced tumor-selective cell killing

Cell Death and Disease

Volumn 3, Issue 4, 2012, Pages

  Zimmerman, R ^a   Peng, D J ^a,b   Lanz, H ^a   Zhang, Y H ^a   Danen Van Oorschot, A ^a   Qu, S ^b   Backendorf, C ^a   Noteborn, M ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptin; Apoptosis; BCA3 AKIP1; PKA; PP2A; SV40 LT and ST

Indexed keywords

ANTIGEN; APOPTIN; CYCLIC AMP; PHOSPHOPROTEIN PHOSPHATASE 2A; SV40 LARGE T ANTIGEN; UNCLASSIFIED DRUG; AKIP1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOQUINOLINE DERIVATIVE; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; NUCLEAR PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; SULFONAMIDE; VIRUS T ANTIGEN;

ARTICLE; CELL DEATH; CELL KILLING; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MUTATIONAL ANALYSIS; ONCOGENIC TRANSFORMATION ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; APOPTOSIS; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; HELA CELL; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; PROTEIN SUBUNIT; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; FIBROBLASTS; HELA CELLS; HUMANS; ISOQUINOLINES; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; PROTEIN PHOSPHATASE 2; PROTEIN SUBUNITS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 84861461244     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.31     Document Type: Article

References (40)

1. Wenner CE. Cell signaling and cancer-possible targets for therapy. J Cell Physiol 2010; 223: 299-308.
2. Bruno P, Brinkman CR, Boulanger M-C, Flinterman M, Klanrit P, Landry MC et al. Family at last: highlights of the first international meeting on proteins killing tumour cells. Cell Death Diff 2009; 16: 184-186.
3. Backendorf C, Visser AE, De Boer AG, Zimmerman R, Visser M, Voskamp P et al. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol 2008; 48: 43-69.
4. Grimm S. Noteborn MHM. Anticancer genes: inducers of tumour-specific cell death. Trends Mol Med 2010; 16: 88-96.
5. Pipas J. SV40: cell transformation and tumorigenesis. Virology 2009; 384: 294-303.
6. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Mary W, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468. (Pubitemid 29361801)
7. Sablina AA, Hector M, Colpaert N, Hahn WC. SV40 small antigen and PP2A phosphatase in cell transformation. Cancer Res 2008; 70: 10474-10484.
8. Chen Y, Xu Y, Bao Q, Xing Y, Li Z, Lin Z et al. Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat Struc Mol Biol 2007; 6: 527-534. (Pubitemid 46871815)
9. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, Xu W. Structural basis of PP2A inhibition by small T antigen. PLoS Biol 2007; 5: e202.
10. Sablina AA, Hahn WC. SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 2008; 27: 137-146.
11. Westermarck J, Hahn W. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160.
12. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M et al. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009; 13: 83-92.
13. Usui H, Inoue R, Tanabe O, Nishito Y, Shimizu M, Hayashi H et al. Activation of protein phosphatase 2A by cAMP-dependent protein kinase-catalyzed phosphorylation of the 74-kDa B00 (delta) regulatory subunit in vitro and identification of the phosphorylation sites. FEBS Lett 1998; 430: 312-316. (Pubitemid 28337935)
14. Kitching R, Li H, Wong MJ, Kanaganayakam S, Kahn H, Seth A. Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternative spliced proline-rich protein. Biochim Biophys Acta 2003; 1625: 116-121. (Pubitemid 36084509)
15. Zhang Y-H, Kooistra K, Pietersen AM, Rohn JL. Noteborn MHM. Activation of the tumorspecific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen. J Virol 2004; 78: 9965-9976. (Pubitemid 39187115)
16. Srinivasan A, McClellan AJ, Vartikar J, Marks I, Cantalupo P, Li Y et al. The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain. Mol Cell Biol 1997; 17: 4761-4773. (Pubitemid 27318151)
17. Rohn JL, Noteborn MHM. The viral death effector apoptin reveals tumor-specific processes. Apoptosis 2004; 9: 315-322. (Pubitemid 38981505)
18. Alvisi G, Poon IK, Jans DA. Tumor-specific nuclear targeting: promises for anti-cancer therapy. Drug Resist Update 2006; 9: 40-50. (Pubitemid 43928804)
19. Mungre S, Enderle K, Turk B, Porras A, Wu Y-Q, Mumby MC et al. Mutations which affect the inhibition of protein phosphatase 2A by simian virus 40 small-t antigen in vitro decrease viral transformation. J Virol 1994; 68: 1675-1681. (Pubitemid 24065734)
20. Sastri M, Barraclough DM, Carmichael PT, Taylor SS. A kinase-interacting protein localizes protein kinase A in the nucleus. Proc Natl Acad Sci USA 2005; 102: 349-354. (Pubitemid 40116770)
21. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006; 24: 261-274. (Pubitemid 46435008)
22. Bulun SE, Simpson ER. Aromatase expression in women's cancers. Adv Exp Med Biol 2008; 630: 112-132.
23. Ahn J-H, McAvoy T, Rakhilin SV, Nishi A, Greengard P, Naim AC. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56d subunit. Proc Natl Acad Sci USA 2007; 104: 2979-2984. (Pubitemid 46327989)
24. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746-7755. (Pubitemid 41670676)
25. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5: 127-136. (Pubitemid 38283799)
26. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009; 33: 537-545.
27. Li H, Cai X, Shouse GP, Piluso LG, Liu X. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 2007; 26: 402-411. (Pubitemid 46160941)
28. Foley EA, Maldonado M, Kapoor TM. Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase. Nat Cell Biol 2011; 10: 1265-1271.
29. Kucharski TJ, Gamache I, Gjoerup O, Teodoro JG. DNA damage response signaling triggers nuclear localization of the chicken anemia virus protein Apoptin. J Virol 2011; 85: 12638-12649.
30. Pihan GA, Doxsey SJ. The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 1999; 4: 289-302. (Pubitemid 29429993)
31. Ben-Israel H, Sharf R, Rechavi G, Kleinberger T. Adenovirus E4orf4 protein downregulates Myc expression through interaction with PP2A-B55 subunit. J Virol 2008; 82: 9381-9388.
32. Zhao RY, Elder RT. Viral infections and cell cycle G2/M regulation. Cell Res 2005; 115: 143-149. (Pubitemid 41653936)
33. Maddika S, Mendosa FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10-19. (Pubitemid 43234971)
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
35. AAAM Danen-Van Oorschot, Voskamp P, MCMJ Seelen, MHAM Miltenburg, Bolk MW, Tait SW et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004; 11: 564-573. (Pubitemid 38660141)
36. Yamashita K, Ikenaka Y, Kakutani T, Kawaharada H, Watanabe K. Comparison of human lymphotoxin gene expression in CHO cells directed by genomic DNA or cDNA sequences. Agric Biol Chem 1990; 54: 2801-2809.
37. Gjoerup O, Zaveri D, Roberts TM. Induction of p53-independent apoptosis by simian 40 small t antigen. J Virol 2001; 75: 142-155.
38. Schmidt TGM, Skerra A. The Strep-tag system for one-strep purification and high-affinity detection or capturing of proteins. Nature Protoc 2007; 2: 1528-1535. (Pubitemid 46952331)
39. Rohn JL, Zhang Y-H, RIJM Aalbers, Otto N, Den Hertog J, Henriquez NV et al. A tumorspecific kinase activity regulates the viral death protein apoptin. J Biol Chem 2002; 277: 50820-50827. (Pubitemid 36042247)
40. Boutros M, Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev Genet 2008; 9: 554-566. (Pubitemid 351861541)